Answers are grounded in this paper and cite their sources.
Corrado Barbui, Cinzia Baschirotto, and Andrea Cipriani find that the results of phase III studies are poorly and inconsistently documented in the EMA’s drug assessment reports. Better reporting would make them more useful for doctors, researchers, and consumers
No takes yet. Share an insight, caveat, or question.
Barbui et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: